TITLE:
Impact of Medical Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia on Male Sexuality
AUTHORS:
Thierno Oumar Diallo, Alimou Diallo, Alpha Oumar Barry, Emmanuel Duval Arnaud Aka, Mamadou Dian Barry, Thierno Mamadou Oury Diallo, Daouda Kanté, Mamadou Diao Bah, Abdoulaye Bobo Diallo, Oumar Raphiou Bah
KEYWORDS:
BPH, IIEF-5 Score, Medication Treatment, Sexual Dysfunction, Ejaculation, Sexuality
JOURNAL NAME:
Open Journal of Urology,
Vol.15 No.1,
January
26,
2025
ABSTRACT: Introduction: Benign prostatic hyperplasia (BPH) is a benign neoplasm that develops from the constituent elements of the prostate. It is a common age-related condition, with more than 50% of men over 50 years old exhibiting symptoms indicative of BPH. It is the main cause of lower urinary tract symptoms (LUTS). Materials and Methods: This was a prospective, descriptive and longitudinal study over a six-month period from December 15, 2023, to May 15, 2024. All patients admitted for BPH and who received medication treatment during this period were included in the study. Results: The average age of patients was 65.4 years, with the 60 to 69-year age group being the most represented (37.18%). There was no statistical link between the level of education and the occurrence of erection dysfunction ED. 66.67% of patients suffered from ED before treatment. Age was a major risk factor. 94.87% of patients were treated with Alpha-blockers due to their tolerance and effectiveness. 14.10% of patients had a history of inguinal herniorrhaphy, often due to the strain of urination and physical labor. 46.16% of patients had hypertension. No significant link was found between comorbidities and ED. 38.45% of patients consumed tobacco or alcohol. Tobacco was a significant risk factor for ED. 57.67% of patients suffered from ED after treatment, indicating an improvement compared to 66.67% before treatment. However, 24.36% did not ejaculate during sexual intercourse. Conclusion: Medication treatment is the first-line treatment for BPH. However, it can lead to retrograde ejaculation, negatively impacting ejaculatory function. The results showed that the treatment improves patients’ sexuality (IIEF-5 score), but age and tobacco consumption increase the risk of sexual dysfunction.